This content is for healthcare professionals only.

This activity is funded by an independent medical education grant from GlaxoSmithKline. This activity is provided by touchIME.
By selecting continue you are confirming that you are a healthcare professional.

Faculty & Disclosures

Listen on the go
    • Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Prof. Nicoletta Colombo

    University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan, Italy

    Prof. Nicoletta Colombo is currently an associate professor of obstetrics and gynaecology at the University of Milan-Bicocca, and director of the Ovarian Cancer Centre and chair of the gynaecology programme at the European Institute of Oncology IRCCS, Milan, Italy. read more

    Nicoletta Colombo graduated in medicine in 1980, completing specialty training in obstetrics and gynaecology in 1984 at the University of Milan, Italy. After a training period at Charing Cross Hospital and Royal Marsden Hospital in London, UK, she became a clinical research associate at the Kaplan Cancer Center, New York University, NY, USA, where she worked from 1984 to 1986. Prof. Colombo then worked as a member of the junior and later the senior faculty at the Department of Obstetrics and Gynaecology at the University of Milan. In 1994, she became deputy director and in 2001, director of the Medical Gynaecologic Oncology Division, European Institute of Oncology (IEO), Milan. Since 2002, she has held the position of associate professor of obstetrics and gynaecology at the University of Milan-Bicocca. In 2008, she became director of the Ovarian Cancer Centre at IEO and in 2014, chair of the Program of Gynaecology. Principal investigator of several international clinical trials, Prof. Colombo is also author of several publications in the field of gynaecologic oncology and a member of various professional societies such as the American Society of Clinical Oncology (ASCO), the Society of Gynaecologic Oncologists (SGO) and the International Gynaecological Cancer Society (IGCS). She is also past president of the European Society of Gynaecologic Oncology (ESGO) and was chair of the first ESMO-ESGO-ESTRO Consensus Conference in endometrial cancer (2015) and the first ESMO-ESGO Consensus Conference in ovarian Cancer (2018). From 2016 until 2020, she was subject editor of the ESMO Clinical Guidelines for Gynaecological Malignancies.

    Prof. Nicoletta Colombo discloses: Grants or contracts from AstraZeneca, PharmaMar and Roche. Honoraria or payment from AstraZeneca, Clovis Oncology, Eisai, GlaxoSmithKline, Merck Sharp and Dohme, Novartis and Tesaro. Participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, BIOCAD, Clovis Oncology, Eisai, GlaxoSmithKline, ImmunoGen, Merck Sharp and Dohme, Mersana, Nuvation Bio, Oncxema, Pfizer, PharmaMar, Roche and Tesaro. Leadership or fiduciary role in other board, society, committee or advocacy group steering committee member on ESMO clinical guidelines and a scientific committee chair for Acto Onlus.
    Dr Natalia R Gómez-Hidalgo

    Vall d'Hebron Hospital, Barcelona, Spain

    Dr Natalia R Gómez-Hidalgo is currently a gynecologic oncologist consultant and surgeon at Vall d’Hebron University Hospital in Barcelona, Spain. read more

    Dr Gómez-Hidalgo graduated in medicine at Complutense University of Madrid, Spain, in 2010. After completing her residency programme in obstetrics and gynaecology in Madrid (2015), she was awarded an International Gynecologic Cancer Society Foundation grant to specialize in gynecologic oncology at the Memorial Sloan Kettering Cancer Center, New York, USA (2015). Afterwards, Dr Gómez-Hidalgo worked as a clinical research coordinator at Columbia University, New York (2017).

    Dr Natalia R Gómez-Hidalgo has no financial interests/relationships or affiliations in relation to this activity.
    Back to Faculty
    touchONCOLOGY touchONCOLOGY
    Now Playing:
    Up Next:
    Take CE/CME Test
    Start activity
     
    The rationale for PARP inhibitors in the first-line maintenance setting
    Identifying patients who may benefit from a PARP inhibitor in the first-line maintenance setting
    Selecting a maintenance treatment regimen for individual patients
    Take CE/CME Test

    touchIN CONVERSATION
    A relaxed discussion between two faculty focussed on real world clinical issues. Useful tips below will show how to navigate the activity. Join the conversation. Close

    Maximizing the potential of PARP inhibitors as first-line maintenance therapy in ovarian cancer: Improving patient identification and treatment selection

    Faculty Podcast Featured
    Useful tips
    • Downloads including slides are available for this activity in the Toolkit
    Learning Objectives

    After watching this activity, participants should be better able to:

    • Discuss the rationale for using PARP inhibitors in the first-line maintenance treatment of advanced ovarian cancer
    • Identify patients who may benefit from a PARP inhibitor in the first-line maintenance setting
    • Describe the key factors that can inform selection of the most appropriate PARP inhibitor for each patient
    Overview

    In this activity, gynaecologic oncology specialists Prof. Nicoletta Colombo and Dr Natalia R Gómez-Hidalgo discuss three key topics relating to PARP inhibitors in the first-line maintenance setting for advanced ovarian cancer – rationale for use, which patients may particularly benefit, and key factors informing PARP inhibitor selection. Discussion on these themes is based on questions posed by healthcare professionals involved in the care of patients with ovarian cancer.

    This activity is CE/CME accredited

    To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.

    Claim Credit
    Useful tips
    • Downloads including slides are available for this activity in the Toolkit

    You may also be interested in...

    CONFERENCE HUB

    Cancer prevention and the power of breastfeeding: PrEvCan | Celia Diez de los Rios

    GO TO HUB

    touchIN CONVERSATION

    Maximizing the potential of PARP inhibitors as first-line maintenance therapy in ovarian cancer: Improving patient identification and treatment selection

    LAUNCH ACTIVITY

    CONFERENCE HUB

    Domenica Lorusso, ASCO 2022: Trabectedin for the treatment of recurrent ovarian, primary peritoneal, or fallopian tube cancers – Phase 3 MITO23 trial results

    GO TO HUB

    touchCONGRESS

    PARP inhibitors as first-line maintenance treatment for ovarian cancer: Translating the latest data to clinical practice

    LAUNCH ACTIVITY

    JOURNALS

    Defining Optimal Treatment in Early-stage Epithelial Ovarian Cancer – When, What and for How Long?

    GO TO ARTICLE

    JOURNALS

    Foreword – European Oncology & Haematology, 2011;7(2):100-100

    GO TO ARTICLE

    Topics covered in this activity

    Ovarian Cancer / Gynaecological Cancers
    Register to touchONCOLOGY for FREE
    • Peer-reviewed journals and expert opinions
    • Interactive CME and e-learning modules
    • Video conference highlights
    Register For Free Now
    This Activity Is Funded By:

    An independent medical education grant from GlaxoSmithKline.
    This activity is provided by touchIME.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended only for healthcare professionals.

    Launch date: 20 July 2022

    Claim Credit
    touchIN CONVERSATION
    Maximizing the potential of PARP inhibitors as first-line maintenance therapy in ovarian cancer: Improving patient identification and treatment selection

    You may also be interested in...

    touchIN CONVERSATION

    Maximizing the potential of PARP inhibitors as first-line maintenance therapy in ovarian cancer: Improving patient identification and treatment selection

    LAUNCH ACTIVITY

    CONFERENCE HUB

    Domenica Lorusso, ASCO 2022: Trabectedin for the treatment of recurrent ovarian, primary peritoneal, or fallopian tube cancers – Phase 3 MITO23 trial results

    GO TO HUB

    JOURNALS

    Pembrolizumab and Chemotherapy in Cervical Cancer: A New Standard of Care?

    GO TO ARTICLE

    touchCONGRESS

    PARP inhibitors as first-line maintenance therapy in ovarian cancer: Using data from SGO 2022 to inform clinical best practice

    LAUNCH ACTIVITY

    CONFERENCE HUB

    Shibani Nicum, ESMO 2021: First Results of the OCTOVA Trial

    GO TO HUB

    JOURNALS

    Defining Optimal Treatment in Early-stage Epithelial Ovarian Cancer – When, What and for How Long?

    GO TO ARTICLE
    This Activity Is Funded By:

    An independent medical education grant from GlaxoSmithKline.
    This activity is provided by touchIME.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended only for healthcare professionals.

    Launch date: 20 July 2022

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup